CYP2E1 plays a suppressive role in hepatocellular carcinoma by regulating Wnt/Dvl2/β-catenin signaling

Lili Zhu¹, Xiaobei Yang¹, Jingyu Feng¹, Jian Mao², Qidong Zhang², Mengru He¹, Yang Mi¹, Yingwu Mei¹, Ge Jin¹ and Haifeng Zhang¹*¹

Abstract

Objective: Knowledge of the role of CYP2E1 in hepatocarcinogenesis is largely based on epidemiological and animal studies, with a primary focus on the role of CYP2E1 in metabolic activation of procarcinogens. Few studies have directly assessed the effects of CYP2E1 on HCC malignant phenotypes.

Methods: The expression of CYP2E1 in HCC tissues was determined by qRT-PCR, western blotting and immunohistochemistry. Overexpression of CYP2E1 in HCC cell was achieved by lentivirus transfection. The function of CYP2E1 were detected by CCK-8, wound healing, transwell assays, xenograft models and pulmonary metastasis model. TOP/FOP-Flash reporter assay, western blotting, functional rescue experiments, Co-immunoprecipitation and reactive oxygen species detection were conducted to reveal the underlying mechanism of the tumor suppressive role of CYP2E1.

Results: CYP2E1 expression is down-regulated in HCC tissues, and this downregulation was associated with large tumor diameter, vascular invasion, poor differentiation, and shortened patient survival time. Ectopic expression of CYP2E1 inhibits the proliferation, invasion and migration and epithelial-to-mesenchymal transition of HCC cells in vitro, and inhibits tumor formation and lung metastasis in nude mice. Mechanistic investigations show that CYP2E1 overexpression significantly inhibited Wnt/β-catenin signaling activity and decreased Dvl2 expression in HCC cells. An increase in Dvl2 expression restored the malignant phenotype of HCC cells. Notably, CYP2E1 promoted the ubiquitin-mediated degradation of Dvl2 by strengthening the interaction between Dvl2 and the E3 ubiquitin ligase KLHL12 in CYP2E1-stable HCC cells. CYP2E1-induced ROS accumulation was a critical upstream event in the Wnt/β-Catenin pathway in CYP2E1-overexpressing HCC cells.

Conclusions: These results provide novel insight into the role of CYP2E1 in HCC and the tumor suppressor role of CYP2E1 can be attributed to its ability to manipulate Wnt/Dvl2/β-catenin pathway via inducing ROS accumulation, which provides a potential target for the prevention and treatment of HCC.

Keywords: CYP2E1, Wnt, β-catenin, Ubiquitination, Dvl2, ROS, Hepatocellular carcinoma
Introduction

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally and its incidence continues to rise [1]. Currently, treatment options for advanced HCC patients are quite limited, resulting in an extremely low 5-year survival rate. HCC is associated with hepatitis B virus, hepatitis C virus, alcohol, aflatoxin and nitrosamines. However, the underlying molecular mechanisms involved in tumor formation and pathogenesis are unclear. Therefore, it is imperative to identify new molecular targets for the diagnosis and therapy of HCC.

Cytochrome P450 (CYP) enzymes are a superfamily of hemoproteins and extensively catalyze the metabolism of exogenous and endogenous compounds. CYP also exerts a crucial role in the development and progression of cancer, diabetes, heart disease, and Parkinson’s disease [2–5]. CYP2E1 is the most abundant CYP isoform in human liver and is the main enzyme that metabolizes a number of low molecular weight compounds, such as ethanol, acetaminophen, benzene, and carbon tetrachloride, and cancer suspects like nitrosamines and azo compounds [6, 7]. Owing to its contribution to the metabolic activation of procarcinogens, many studies have explored the relevance of CYP2E1 to HCC susceptibility. For example, CYP2E1 catalyzes alcohol oxidation to acetaldehyde under long-term consumption of ethanol, and acetaldehyde forms DNA adducts, which may play an important role in hepatocarcinogenesis in patients with alcoholic liver injury [8]. In addition, CYP2E1 converts diethylnitrosamine to genotoxic products which damage DNA irreversibly, leading to hepatocarcinogenesis in rat studies.

However, the most common etiology of HCC is viral infection (hepatitis B virus and hepatitis C virus), not procarcinogens. Especially in China, 85% of HCC cases are associated with chronic HBV infection [9, 10]. Our knowledge of CYP2E1 in non-procarcinogen-related HCC is limited. Recently, several groups independently revealed that both the expression level and the activity of CYP2E1 are decreased in HCC as compared to adjacent normal liver tissues [11, 12]. From liver lesion and cirrhosis to the tumor occurrence, in the rat HCC model of hepatocarcinogenesis the expression level of CYP2E1 gradually decreased with the aggravation of liver lesion [13]. As the downregulation of CYP2E1 occurred earlier than the onset of tumor occurrence, it was possible that decreased CYP2E1 might play a role in hepatocarcinogenesis. Indeed, decreased CYP2E1 was associated with poorly differentiated HCC and poor prognosis of patients with HCC [14]. These findings imply that high expression of CYP2E1 might have an inhibitory role in HCC development. In fact, elevated CYP2E1 level by alcohol induction [15], ectopic expression [16, 17], or exposure to TSA [18] is cytotoxic to HCC cells and inhibits their rapid proliferation. Thus, CYP2E1 may play multiple roles at different stages during hepatocarcinogenesis, which merits more detailed investigation.

CYP2E1 has been shown to be involved in many signaling pathways, such as the AKT [19], PPARα[20], EGFR/c-Raf, ERK1/2 [21], MAPK [22], Nrf2/HO-1, NF-κB [23], and the JNK pathways [24]. Wnt/β-catenin signaling is frequently deregulated in HCC, where activation of Wnt leads to HCC initiation, progression, invasion, and metastasis [25]. Up to 70% of HCCs exhibit increased
Wnt/β-catenin signaling, and CTNNB1 (β-catenin) mutations are elevated with HCC progression [26]. However, the relationship between CYP2E1 and Wnt/β-catenin signaling is unknown.

The current study was designed to unravel the roles of CYP2E1 in the pathogenesis of HCC. We investigated: (1) whether CYP2E1 has a protective role in the malignant biological behavior of HCC; (2) if so, whether CYP2E1 acts as a tumor suppressor by regulating the Wnt/β-catenin pathway in HCC, and (3) the potential links between CYP2E1 suppression and the Wnt/β-catenin pathway in HCC.

Materials and methods

Patients and tissue samples

A total of 88 HCC and adjacent non-tumor tissues were collected from patients who underwent liver cancer hepatectomy at the Affiliated Cancer Hospital of Zhengzhou University (Zhengzhou, China) from July 2016 to December 2017, of which 81 samples were paired. Detailed information of the sample refers to Additional file 1: Table S1. The ethics committee of Zhengzhou University approved the protocol (18 March 2016; Approved No: 2016-0177) and all the patients gave written informed consent. In addition, all specimens were subjected to RT-qPCR after RNA extraction, and 36 and 20 samples were used for western blot and immunohistochemical verification, respectively.

Cell culture and reagents

Human liver cell lines SMMC-7721, HepG2, MHCC-97H, Huh7, Bel-7402 were donated by Dr. Tingting Liu (Sino-American Hormelian Cancer Research, Zhengzhou, P.R. China) and Prof. Ping Xu (State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences, Beijing, P.R. China). HCC-LM3 was purchased from China Center for Type Culture Collection (Wuhan, China). All cell lines were cultured at 37 °C with 5% CO2 and grown in Dulbecco’s modified Eagle’s medium (BI, Shanghai) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. 3-Methyladenine (3-MA) was provided by Santa Cruz Biotechnology (sc-205596). N-Acetyl-l-cysteine (NAC) and the CYP2E1 inhibitor clomethiazole (CMZ) was purchased from Yuanye Biotechnology (Shanghai, China).

RT-qPCR

RT-qPCR was performed according to our previous study [6] and the primers used are listed in Additional file 1: Table S2. Briefly, total RNA was extracted by the RNAiso Plus kit (Takara Bio Inc.). The PrimeScript RT reagent kit (Takara Bio Inc) was used to synthesize the cDNA from 1 μg of total RNA. The transcript levels of the target genes were measured by an ABI 7500 Fast Real-Time PCR system. GAPDH was used as a reference gene.

Western blot

Western blot assays were performed as described recently [27]. Briefly, cells were lysed on ice and proteins were fractionated by SDS-PAGE. Then the protein was transferred onto a PVDF membrane, which was incubated with the indicated antibody and ECL solution. The signal was visualized with an ECL detection system. Antibodies used include anti-CYP2E1 (ab28146, from Abcam, UK); anti-c-Myc (10828-I-AP), Goat anti-rabbit IgG (HL) (SA00001-2), anti-β-Catenin (66379-1-Ig), goat anti-mouse IgG (HL) (SA00001-1), anti-LEF1 (14972-1-AP) (from Proteintech, Wuhan, China); anti-GAPDH (6C5, sc-47724), anti-β-actin (C4, sc-47778), anti-Dvl2 (D-11, sc-390303), anti-TCF-4 (D-4, sc-166699), anti-KLHL12 (D-1, sc-514874), anti-Ub antibody (P4D1, sc-8017) (from Santa Cruz Biotechnology, Inc, USA); anti-E-cadherin (WL01482), anti-Twist (WL00997), anti-N-cadherin (WL01047), anti-Snail (WL01863), anti-Vimentin (WL01960), and anti-Slug (WL01508) from Wanlei Life Sciences, Shenyang, China.

Gene expression manipulations

Vector lentivirus and lentivirus encoding human CYP2E1 (EX-I0304-Lv201 and EX-NEG-Lv201) were provided by GeneCopoeia (Guangzhou, China). Control or CYP2E1 vectors were first mixed with packaging plasmids (Lenti-Pac™ HIV, GeneCopoeia company) and then were co-transfected into HEK293T cells by Lipofectamine 2000 (Thermo Fisher Scientific Inc). Culture supernatants were collected and purified (LPR-LCS-01, GeneCopoeia, Guangzhou, China) at 48 h after transfection. In the presence of 8 μg/ml polybrene, MHCC-97H and SMMC-7721 cells were infected with the virus particles and finally, puromycin was used to select the infected cells. The over-expression of CYP2E1 in transfected cells was verified by RT-qPCR and western blot. To overexpress Dvl2, the full-length Dvl2 plasmid (GV417-Dvl2) was transiently infected into the CYP2E1 stable cells by VigoFect (Vigorous Biotechnology).

Cell migration assay

For cell migration assay, HCC cells were plated in 6-well plates and grown to confluence. The cell monolayer was
scratched with a sterile 10 μl pipette tip and exchanged with serum-free DMEM after washing twice with PBS. The images of the wounds were recorded at the same position using an inverted microscope (Nikon ECLIPSE TS100, Japan) at 0 h, 24 h, 48 h and 72 h, respectively. The width between wounds was detected by Image J software (National Institutes of Health).

**Cell invasion assay**

For cell invasion capacity, the Transwell chamber was coated with 100 μl 1: 8 diluted Matrigel (BD BioCoat, Corning, USA) and incubated for 5 h. Next, 5 × 10^4 cells in serum-free medium (200 μl) was seeded at the upper chamber, and 600 μl of DMEM medium containing 10% FBS was added to the lower chamber. After 36 h incubation at 37 °C, the matrigel in the upper chamber was gently removed using a cotton swab. The invaded cells were fixed with paraformaldehyde (4%) and stained with DAPI. The cells were photographed using fluorescence microscopy and counted from 5 random fields of microscope.

**CCK-8 assay**

200 μl of cell suspension (5 × 10^3 cells) were added into 96-well plates and incubated at 37 °C. At the appointed time, each well was added with 10 μl CCK-8 reagent (Dojindo Laboratories, Japan) and the absorbance at 450 nm was determined by a microplate spectrophotometer (BioTek, USA).

**TOPFlash reporter assay**

HCC-Ctrl or HCC-CYP2E1 cells were seeded in 24-well plates and incubated for 24 h at 37 °C. Then the cells were transfected with TOPFlash plasmid (800 ng/well) and pRL-TK plasmid (50 ng/well) using VigoFect reagent (Vigorous Biotechnology). The Dual Luciferase Reporter Assay Kit (Promega, Madison, WI, USA) was employed to measure Luciferase and Renilla activities 48 h after transfection. The luciferase activity of each sample was normalized with the respective Renilla activity.

**Detection of reactive oxygen species (ROS)**

Cells grown to the appropriate 70–80% confluence in 6-well plates were stained with 20 μmol/l dihydroethidium (DHE, ABP Biosciences, Germany) for 1 h in the dark to assess the ROS level. ROS generation was indicated by red fluorescence and detected at Em: 485 nm and Ex: 610 nm with a fluorescence microscope.

**Co-immunoprecipitation (co-IP) experiment**

Protein extraction and quantification are as described for western blotting. Briefly, total protein (800 μg) was pre-cleared with Protein A/G agarose (sc2003; Santa Cruz) at 4 °C for 30 min to remove non-specific protein. After centrifugation, the precleared supernatant was incubated with 2 μg of primary antibodies at 4 °C overnight and then 40 μl Protein A/G agarose was added and incubated at 4 °C for 4 h. Next, the agarose beads were collected by centrifugation at 3000 rpm and extensively washed with RIPA lysis buffer. Finally, the bound proteins were mixed with loading buffer and subjected to western blotting analysis. Mouse IgG was used as a negative control.

**Immunohistochemistry**

Liver tissues were embedded with paraffin, sectioned, dewaxed, and dehydrated with gradient ethanol. After antigen repair, the slides were incubated with CYP2E1 antibody (ab28146, Abcam; 1:125 dilution) at 4 °C overnight. Then, the slides were washed with TBST and incubated with HRP-conjugated secondary antibody polymer (SA00001-2, Proteintech, Wuhan, China; 1:250 dilution) followed by the addition of DAB solution and counterstained with hematoxylin.

**Immunofluorescence cell staining**

The cells seeded on the coverslips in the 24-well plates were cultured for 24 h. After fixing with 4% paraformaldehyde and permeabilizing with 0.5% Triton X-100, the cells were incubated with mouse anti-E-cadherin (2:250 dilution, AF0138, Beyotime) and rabbit anti-vimentin (2:250 dilution, 10366-1-AP, proteintech) at 4 °C overnight and then with fluorescence secondary antibodies (CoraLite 594, SA00013-3, goat anti-mouse IgG, Proteintech, 1:500 dilution; CoraLite 594, SA00013-4, goat anti-rabbit IgG, Proteintech, 1:500 dilution) for 30 min at 37 °C. DAPI was used to stain the nuclei for 5 min and coverslips were mounted. Then, the cells were observed by the fluorescence microscope (OLYMpusBX43).

**Tumor xenografts model**

Four-week-old male BALB/c nude mice were provided by the Beijing Vital River Laboratory Animal Technology Company. After habituation for 3 days, 100 μl of MHCC-97H-GFP or MHCC-97H-CYP2E1 cell suspension (1 × 10^7 cells/ml) were injected subcutaneously into the right flanks of mice. Tumor volumes was recorded every 3 days. Tumor volume was calculated with the formula of \( V = \frac{1}{2} \times \text{length} \times \text{width}^2 \). At 35 days after injection, the nude mice were euthanized and tumors were collected for the subsequent orthotopic liver tumor model. These animal experiments were approved by the Animal Ethics Committee of Zhengzhou University and carried out in accordance with the guidelines of animal ethics.

**Mouse liver orthotopic transplantation model**

The tumors taken from the above xenograft nude mice were immediately minced into small pieces (about 1.5 mm × 1.5 mm × 1.5 mm). The left lobe of the liver of the 4.5-week-old male mice was extruded under
Fig. 1  CYP2E1 level is downregulated in HCC and the low expression of CYP2E1 is negatively related to malignant clinicopathologic features of HCC patients.  

A  CYP2E1 mRNA levels in adjacent nontumor tissues and HCC tissues were analyzed by RT-qPCR (n = 88).  

B  CYP2E1 protein levels in paired adjacent nontumor (N) and tumor (T) tissues measured by western blot assay.  

C  Representative images of IHC staining for CYP2E1 in paired adjacent nontumor and tumor tissues.  

D–H  The effect of tumor size (D), vascular invasion (E), degree of differentiation (F), smoking (H), and alcohol consumption (I) on CYP2E1 mRNA level in tumor tissues.  

G  Kaplan–Meier curves for overall survival in HCC patients with variable CYP2E1 expression.
anesthetization and a tunnel was made by a 10 ml syringe needle. Then 2 pieces of the tumors were deposited into the left lobe through the tunnel. Subsequently, the left lobe of the liver was returned to the abdominal cavity, and the muscle and skin were sutured. Ten weeks after the operation, the livers were removed and orthotopic tumors were counted.

**Pulmonary metastasis model**

200 μl of MHCC-97H-GFP or MHCC-97H-CYP2E1 cell suspension (1 × 10^6 cells/ml) were injected into the tail vein of 4.5-week-old mice. At the 9th week the nude mice were euthanized and the lungs removed. The lungs were fixed with 4% paraformaldehyde, embedded in paraffin, and cut into slices. The slices were moved onto glass slides, dewaxed, rehydrated in ethanol solution and followed by the addition of hematoxylin and eosin to determine the metastasis of cancer cells.

**Statistical analyses**

SPSS version 21.0 and GraphPad Prism 5.0 were used to perform statistical analysis and generate graphs, respectively. The Kolmogorov–Smirnov and Shapiro–Wilk methods were used to assess the normality of the data. For normal distribution data, a two-tailed Student’s t-test was used for pairwise comparisons. The Mann–Whitney U-test was used to compare two groups with non-normal distribution data. The overall survival data were analyzed by Kaplan–Meier plots and the cut-off value for defining the subgroups was the median expression level of CYP2E1 mRNA. The sample was then divided into two groups. One group consisted of samples with CYP2E1 expression levels higher than the median, and the other group consisted of the remaining samples. A P value (two-tailed) < 0.05 indicated statistically significant.

**Results**

CYP2E1 is downregulated in HCC tissues and the low expression of CYP2E1 is negatively correlated to the malignant clinicopathological features

The expression level of CYP2E1 mRNA in 88 human HCC specimens was determined by qPCR. The results show that CYP2E1 expression in the tumor tissues was markedly down-regulated compared with the adjacent nontumor tissues (Fig. 1A). Downregulation of CYP2E1 protein was also confirmed by western blotting and IHC assays in 77.8% (28/36) and 75% (15/20) of the tumor tissues, respectively (Fig. 1B, C). Patients with larger tumor sizes (>5 cm) or vascular invasion showed substantially reduced CYP2E1 expression compared with those with smaller tumor sizes (<5 cm) (P < 0.049) (Fig. 1D) or without vascular invasion (P = 0.046) (Fig. 1E). More strikingly, the expression level of CYP2E1 gradually decreased from well and moderately differentiated to poorly differentiated tumor tissues (P < 0.05) (Fig. 1F). Kaplan–Meier analysis revealed that HCC patients with low expression of CYP2E1 demonstrated a lower overall survival compared with those with high expression of CYP2E1 (median survival 21.7 months versus > 40.4 months (P = 0.0248) (Fig. 1G). These data indicate that low CYP2E1 expression may play an important role in promoting HCC malignant progression and CYP2E1 can be used as a potentially valuable biomarker for predicting the prognosis of HCC. In addition, we found that smoking and drinking decreased the expression level of CYP2E1 in tumor tissues, respectively (Fig. 1H, I).

**Overexpression of CYP2E1 inhibits the proliferation, migration and invasion of HCC cell both in vitro and in vivo**

The expression of CYP2E1 mRNA was low in all six HCC cell lines we examined (Additional file 2: Fig. S1A). We then constructed stable expression of CYP2E1 in MHCC-97H and SMMC-7721 cells, which showed the lowest expression of endogenous CYP2E1, using a lentiviral system (MHCC-97H-CYP2E1, SMMC-7721-CYP2E1) (Fig. 2A and Additional file 2: Fig. S1B). Cell Counting Kit-8 assays, wound healing and Transwell assays with MHCC-97H-CYP2E1, SMMC-7721-CYP2E1 cells revealed that the exogenous expression of CYP2E1 significantly inhibited cell proliferation, migration and invasion in comparison with that of control cells (MHCC-97H-GFP, SMMC-7721-GFP) (Fig. 2B–D).

(See figure on next page.)

**Fig. 2** Overexpression of CYP2E1 inhibits the proliferation, migration, and invasion of HCC cell both in vitro and in vivo. A CYP2E1 protein expression was evaluated by western blotting in control and CYP2E1-overexpressing HCC cells. B The effect of CYP2E1 overexpression on cellular survival as determined by CCK-8 assays. C Representative images from scratch wound assays of MHCC-97H-CYP2E1 (left panel), SMMC-7721-CYP2E1 (middle panel), and the respective control cells (x 100). Statistical graphs of scratch wound assays (right panel). D Representative images and statistical analysis (down panel) of Transwell assays for MHCC-97H-CYP2E1, SMMC-7721-CYP2E1, and the respective control cells (x 100). E Image and growth curve of xenograft tumors in nude mice injected with the indicated cells (n = 3 in each assay). F Images of the liver orthotopic transplantation tumors in nude mice implanted with the subcutaneous tumors from MHCC-97H-CYP2E1 or MHCC-97H-GFP cells. G Representative H & E images of lung tissue slides of nude mice injected by tail vein with MHCC-97H-CYP2E1 and MHCC-97H-GFP. The data in B–E are presented as the means ± sd. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 vs. control group.
To confirm the consequences of CYP2E1 overexpression in vivo, we first injected MHCC-97H-CYP2E1 and MHCC-97H-GFP cells into the right dorsal flank of nude mice. Tumors were visible at day 5 with MHCC-97H-GFP cells and grew rapidly after the 8th day of injection, whereas the group injected with MHCC-97H-CYP2E1 cells developed visible tumors on the 17th day of injection and the tumors grew very slowly. At day
after injection, two groups of nude mice were euthanized and the tumors that developed from MHCC-97H-CYP2E1 cells were significantly smaller and lighter than tumors from the control group (Fig. 2E). Next, the subcutaneous tumors from the above two groups of nude mice were used for the liver orthotopic transplantation tumor model experiment. After 10 weeks of implantation, two groups of nude mice were euthanized and the livers removed. The results show that tumors formed in the livers of all 5 mice in the control group, whereas tumors were only observed in 3/5 nude mice with MHCC-97H-CYP2E1 subcutaneous tumor implantation and were significantly smaller (Fig. 2F). Further, lung metastasis was also detected using MHCC-97H-CYP2E1 and MHCC-97H-GFP by tail vein injection. H&E staining of lung tissue sections revealed that fewer and smaller micrometastatic lesions in lungs from nude mice injected with CYP2E1-overexpressing cells compared with those injected with control cells (Fig. 2G). Therefore, the above results demonstrate that CYP2E1 is capable of suppressing the aggressive and highly metastatic phenotype of HCC both in vitro and in vivo.

**Overexpression of CYP2E1 inhibits the Wnt/β-catenin signaling pathway by promoting the ubiquitin-mediated degradation of Dvl2**

To uncover further the molecular mechanism by which CYP2E1 inhibits the malignant phenotype of HCC, we first performed a TOPFlash reporter assay to observe the effect of CYP2E1 on Wnt/β-catenin signaling. The result demonstrated that CYP2E1 overexpression significantly reduced the β-catenin/T-cell factor 4 (TCF4)-dependent transcriptional activity both in MHCC-97H and SMMC-7721 cells (Fig. 3A). Next, we examined the effect of CYP2E1 on the expression of the important Wnt/β-catenin pathway members in HCC cells and found that the protein levels of Dvl2 (Dishevelled 2), β-catenin, TCF4, LEF1 (lymphoid enhancer factor 1) and c-Myc were decreased in SMMC-7721-CYP2E1 and MHCC-97H-CYP2E1 cells compared with their control cells (Fig. 3B). Chloromethiazole (CMZ), a specific inhibitor of CYP2E1, performs its inhibitory action by reducing the protein level of CYP2E1 as well as acting as a non-competitive inhibitor of CYP2E1 [17, 28]. Treatment with the CYP2E1 inhibitor CMZ (40 μM), which obviously reduced CYP2E1 protein levels, significantly restored the protein levels of Wnt pathway proteins in CYP2E1-overexpression cells (Fig. 3C). Moreover, the inhibitory effect of CYP2E1 overexpression on cell proliferation, invasion and migration was significantly rescued by CMZ (Fig. 3D–F). Thus, we conclude that CYP2E1 negatively regulates the Wnt/β-catenin signaling pathway.

Dvl2 plays a core role in the Wnt signaling pathway [29]. The above results suggest that CYP2E1 may exert its Wnt-regulatory function via Dvl2. We ectopically expressed Dvl2 and found that forced expression of Dvl2 restored the protein level of Dvl2, β-catenin, and c-Myc (Fig. 4A) as well as the inhibitory effect of CYP2E1 overexpression on cell proliferation in CYP2E1-overexpressing cells (Fig. 4B). Collectively, these results indicate that CYP2E1 inhibits the malignant phenotype of HCC by negatively regulating Wnt signaling via downregulation of Dvl2. Interestingly, overexpression of CYP2E1 in HCC cells did not affect the mRNA level of Dvl2 and β-catenin (Fig. 4C), which suggests that the downregulation of Dvl2 by CYP2E1 may result from protein stabilization. Previous studies revealed that the ubiquitin–proteasome pathway regulated Dvl2 degradation [30]. We then speculated that CYP2E1 may function in HCC cells similarly. Indeed, overexpression of CYP2E1 markedly increased the protein polyubiquitination of Dvl2 (Fig. 4D). We then treated HCC cells with the proteasome inhibitor MG132 (10 mM) for 1 h and found that the Dvl2 protein level in the CYP2E1-overexpressing cells was significantly restored (Fig. 4E), suggesting that the Dvl2 decrease in CYP2E1-overexpressing HCC cells may involve a ubiquitin-dependent pathway. The activation of the ubiquitin–proteasome pathway requires E3 ubiquitin ligase to specifically recognize the substrate molecule. KLHL12 was the identified E3 ubiquitin ligase of Dvl2 [30]. Next, we determined if the degradation of Dvl2 by CYP2E1 was related to KLHL12. Western blot results showed that there was no difference in KLHL12 protein expression levels between the CYP2E1-overexpressing cell and
Fig. 3 (See legend on previous page.)
the control cells (Fig. 4F), indicating that CYP2E1 did not affect the protein level of KLHL12. We then performed reciprocal Co-IP assays and the results displayed that Dvl2 interacted with KLHL12 and CYP2E1 overexpression enhanced the interaction between Dvl2 and KLHL12 compared with the control group (Fig. 4G). Taken together, these results indicate that CYP2E1 promotes the ubiquitin-mediated degradation of Dvl2 by enhancing the interaction between KLHL12 and Dvl2.

CYP2E1-mediated inhibition of the HCC phenotype as well as the Wnt/β-catenin signaling pathway is ROS-dependent

A unique property of CYP2E1 is to produce reactive oxygen species (ROS). We investigated whether CYP2E1-mediated inhibition of the HCC phenotype as well as Wnt/β-catenin pathway is ROS-dependent. An increased level of intracellular ROS was seen in both MHCC-97H-CYP2E1 and SMMC-7721-CYP2E1 cells in comparison with their corresponding control cells (Fig. 5A). Treatment of the control group and CYP2E1-overexpressing cells with the CYP2E1 inhibitor CMZ (40 μM) or the antioxidant NAC (10 mM) for 6 h showed that the ROS content of CYP2E1-overexpressing cells decreased significantly after CMZ or NAC treatment (Fig. 5A and Additional file 3: Fig. S2). At the same time, the inhibitory effect of CYP2E1 on cell proliferation, migration and invasion was significantly rescued by NAC (Fig. 5B–D). In addition, the protein levels of Dvl2, β-catenin, TCF4 and c-Myc in CYP2E1-overexpressing cells was significantly downregulated in HCC tissues compared with their control cells (Fig. 5E). These results indicate that CYP2E1-mediated inhibition of the HCC phenotype as well as the Wnt/β-catenin signaling pathway is ROS-dependent.

Overexpression of CYP2E1 inhibits EMT in HCC cells

Interestingly, CYP2E1-overexpressing cells show an epithelial cobblestone-like morphology (Fig. 6A). Considering the changes in the morphology of these cells and the function of CYP2E1, we speculate that CYP2E1 may inhibit the EMT of cells. Indeed, overexpression of CYP2E1 increased the expression of epithelial marker (E-cadherin) and decreased the expression of mesenchymal marker (N-cadherin and vimentin) in MHCC-97H and SMMC-7721 cells (Fig. 6B). The immunofluorescence results also exhibited that the expression of E-cadherin increased, while the expression of vimentin decreased in CYP2E1-overexpressing HCC cells (Fig. 6C). In addition, the protein level of EMT-associated transcriptional factors, including Twist, Snail and Slug, were significantly decreased in CYP2E1-expressing cells (Fig. 6B). Thus, overexpression of CYP2E1 inhibits EMT in HCC cells.

Discussion

Our knowledge of the role of CYP2E1 in hepatocarcinogenesis is based on epidemiological and animal studies, with a primary focus on the role of CYP2E1 in the metabolic activation of procarcinogens; few studies have directly assessed the effects of CYP2E1 on HCC malignant phenotypes. Ho et al. [14] reported that of CYP2E1 expression was significantly downregulated in HCC tissues and might serve as an independent prognostic factor for disease-free survival. Similar findings were reported in some earlier studies [11, 12]. In addition, several reports have proposed that CYP2E1 overexpression is cytotoxic to the tumor cells and inhibits rapid cell proliferation upon ethanol treatment [31, 32]. Here, our results show that the expression of CYP2E1 is decreased in HCC tissues, and low expression of CYP2E1 is associated with larger tumor diameter, vascular invasion, tumor differentiation, and short survival time in patients with HCC. Ectopic expression of CYP2E1 inhibited the proliferation, invasion and migration of HCC cells both in vivo and in vitro. Therefore, a decreased level of CYP2E1 might place the HCC cells at an advantage and favor HCC progression. These results support the hypothesis that CYP2E1 plays a protective role in the malignant biological behavior of HCC.

Wnt/β-catenin signaling is an evolutionarily highly conserved pathway and plays decisive roles in development and tissue homeostasis. Aberrant activation of the Wnt/β-catenin signaling cascade is one of the most frequent molecular events in HCC [33] and conduces
to the initiation, progression, invasion, and metastasis of HCC [25]. When the Wnt ligand binds to its receptor, disheveled (Dvl) is recruited to the ligand-receptor complex, which provides a platform for Axin and GSK3β to bind, resulting in the dissociation of the cytoplasmic destruction complex, preventing β-catenin degradation. β-Catenin then forms a complex with TCF4/LEF1 in the nucleus, leading to the activation of Wnt/β-catenin target genes.
Fig. 5 CYP2E1-inhibited Wnt/β-catenin signaling by ROS. A ROS level in control and CYP2E1-overexpressing HCC cells detected by fluorescence probe and the change in ROS level after treatment with the CYP2E1 inhibitor CMZ (40 μM) or the antioxidant NAC (10 mM) for 6 h in the indicated cells. B The OD450 value of MHCC-97H-CYP2E1, SMMC-7721-CYP2E1 and the respective control cells after treatment with NAC (10 mM) at the indicated time points. C Representative images and statistical analysis (right panel) of scratch wound assays of MHCC-97H-CYP2E1, SMMC-7721-CYP2E1 and the respective control cells after treatment with NAC (10 mM) (×100). D Representative images and statistical analysis (down panel) of transwell assays of MHCC-97H-CYP2E1, SMMC-7721-CYP2E1, and the respective control cells after treatment with NAC (10 mM) (×100). E After treatment with the CYP2E1 inhibitor CMZ (40 μM) or the antioxidant NAC (10 mM) for 6 h, the protein levels of Dvl1-2, β-catenin, TCF4 and c-Myc in MHCC-97H-CYP2E1, SMMC-7721-CYP2E1 and the respective control cells were evaluated by western blot. Data in 5B, 5C and 5D are shown as mean ± sd (n = 3–6 in each assay). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. CYP2E1.
Fig. 6 Overexpression of CYP2E1 inhibits EMT in HCC cells. A Representative images of the morphological changes associated with EMT of MHCC-97H-CYP2E1, SMMC-7721-CYP2E1 and the respective control cells (× 100). B Protein levels of EMT markers (E-cadherin, vimentin and N-cadherin) as well as EMT-related transcription factors (Twist, Slug and Snail) of the indicated cells detected by western blot. C Typical images of immunofluorescent staining for E-cadherin and vimentin in MHCC-97H and SMMC-7721 cells (× 100). D Proposed model of the tumor suppressor role of CYP2E1 in HCC. Overexpression of CYP2E1 induces ROS accumulation and promotes the ubiquitin-mediated degradation of Dvl2, thereby, inhibiting the Wnt/β-catenin signaling and playing a suppressive role in HCC.
genes, such as c-Myc, Axin2, LEF1. Dvl is therefore the central component of Wnt/β-catenin signaling and relays signals from Wnt receptors to β-catenin by rescuing β-catenin from degradation [10, 29]. Three homologous Dishevelled genes (Dvl1, Dvl2 and Dvl3), which exhibit a high degree of similarity, have been found in humans [34]. Increasing evidence indicates that Dvl plays critical roles in the progression of breast cancers, non-small cell lung cancer and astrocytomas [34–36]. A recent study revealed that Dvl2 was overexpressed in HCC tissues and interacted with P62 to promote the invasion and migration of HCC cells [37].

In the present study, CYP2E1 overexpression significantly inhibited Wnt/β-catenin signaling activity in HCC cells and Dvl2 expression level was reduced in CYP2E1-overexpressing HCC cells. Restoration of Dvl2 expression rescued the malignant phenotype of HCC cells. Previous studies have verified that Dvl2 is mainly regulated at the protein level by the ubiquitin–proteasome pathway. We thus speculated that the CYP2E1-blocked Wnt/β-catenin signaling pathway might depend on Dvl2 stability. KLHL12–Cullin-3 ubiquitin ligase was reported to mediate ubiquitination and degradation of Dvl2 under different physiological conditions [30, 38]. Our results demonstrate that overexpression of CYP2E1 promotes the ubiquitination of Dvl2 in HCC cells. Further mechanistic research found that CYP2E1 strengthened the interaction of Dvl2–KLHL12, thus inducing the ubiquitination and degradation of Dvl2 in CYP2E1-stable cells. Therefore, the present study establishes a link between CYP2E1 and Wnt/β-catenin signaling, and indicates that overexpression of CYP2E1 inhibits Wnt/β-catenin signaling by inducing the destabilization and promoting the degradation of Dvl2.

How does CYP2E1 regulate Wnt/β-Catenin signaling? CYP2E1 is one of the most active ROS-generating CYP isoforms and can produce high levels of ROS [39]. ROS are increasingly being recognized as important signaling molecules involved in the regulation of many signaling pathways [40]. Several studies have revealed the ability of ROS to regulate Wnt/β-catenin signaling [41]. For example, H₂O₂ negatively regulates the Wnt pathway by down-regulating β-catenin [42]. Combretastatin A-1 phosphate, a microtubule polymerization inhibitor, has outstanding anti-cancer activity against HCC by inducing ROS accumulation and thereby inhibiting the Wnt/β-catenin pathway in HepG2 cells [43].

A recent finding revealed that oxidative stress suppressed distant metastasis by melanoma cells in vivo [44]. Large-scale multicentre clinical trials also showed that antioxidant supplementation not only failed to bring benefit to patients, but was related with a significant increase in cancer incidence [45, 46]. In the current study, ROS level were significantly elevated in CYP2E1-overexpressing HCC cells comparing with the control cells. Treatment with CYP2E1 inhibitor or antioxidant not only restored the expression of proteins associated with the Wnt signaling pathway but also rescued the inhibitory phenotypes in CYP2E1 stable HCC cells. Therefore, we speculate that the inhibitory effect of CYP2E1 on the Wnt/β-catenin pathway is ROS-dependent and downregulation of CYP2E1 is beneficial to HCC cells to cope with the ROS stress and favor cancer growth.

Collectively, our studies provide novel insight into the role of CYP2E1 in HCC, independent of its activation of procarcinogens and mutagens. Ectopic expression of CYP2E1 inhibits cell proliferation, migration, invasion and EMT of HCC cells in vitro and inhibited tumor formation and lung metastasis in nude mice. The protective effect of CYP2E1 is attributed to its ability to manipulate Wnt/Dvl2/β-catenin signaling through ROS accumulation, which provides a potential target for the prevention and treatment of HCC.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12967-022-03396-6.

**Acknowledgements**

Not applicable.

**Author contributions**

LZ: Conceptualization, methodology, investigation, validation, formal analysis. XY: Conceptualization, methodology, investigation, formal analysis, writing—original draft. JF: Validation, visualization, writing—review and editing, final version. JM, QZ: Conceptualization, methodology, MH, YM: Methodology, investigation. YM: Formal analysis, writing—review & editing, final version. GJ: Project administration. HZ: Conceptualization, methodology, formal analysis, funding acquisition, supervision, writing—original draft, writing—review & editing. All authors read and approved the final manuscript.

**Funding**

This study was supported by Natural Science Foundation of Henan Province (No. 182300410354) and Scientific and Technological Breakthroughs of Henan province (No. 222102310173).

**Availability of data and materials**

The datasets used and analyzed during the current study are included in the manuscript and the supplementary materials.

**Declarations**

**Ethics approval and consent to participate**

This study was carried out according to the principles established by the Declaration of Helsinki and approved by the Ethical Committee of the Zhengzhou University (18 March 2016; Approval No. 2016-0177). All participants were
provided with an informed consent that they signed prior to the experiments. These animal experiments were approved by the Animal Ethics Committee of Zhengzhou University and carried out in accordance with the guidelines of animal ethics.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1 Department of Biochemistry & Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001, Henan, China. 2 Zhengzhou Tobacco Research Institute of China National Tobacco Company, Zhengzhou 450001, China.

Received: 25 January 2022   Accepted: 18 April 2022

Published online: 04 May 2022

References
1. Heinrichs JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.

2. Machalz D, Pach S, Bermudez M, Bureik M, Walter G. Structural insights into understood human cytochrome P450 enzymes. Drug Discov Today. 2021;26(10):2456–64.

3. Gangadhariah MH, Dieckmann BW, Lantier L, Kang L, Wasserman DH, Chiuse M, Caiskey CF, Dickerson J, Luo P, Gamboa JL, et al. Cytochrome P450 epoxyenoxin-derived epoxyeicosatetraenoic acids contribute to insulin sensitivity in mice and in humans. Diabetologia. 2017;60:1066–75.

4. Zhang C, He M, Ni L, He K, Su K, Deng Y, Li Y, Xia H. The Role of arachidonic acid metabolism in myocardial ischemia-reperfusion injury. Cell Biochem Biophys. 2020;78:255–65.

5. Shah A, Ong CE, Pan Y. Unveiling the role of cytochrome P450 (2E1) in hepatocellular carcinoma. World J Gastroenterol. 2015;32:1141–57.

6. Zhang HF, Wang HH, Gao N, Wei JY, Tian X, Zhao Y, Fang Y, Zhou J, Wen Q, Yan B. Protective effects of taraxasterol against ethanol-induced liver injury by regulating CYP2E1/Nrf2/HO-1 and NF-kappaB signaling pathways in mice. Oxid Med Cell Longev. 2018;2018:8284107.

7. Lee M, Bae MA. Docosahexaenoic acid induces apoptosis in CYP2E1-containing HepG2 cells by activating the c-Jun N-terminal protein kinase related mitochondrial damage. J Nutr Biochem. 2007;18:348–54.

8. Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med. 2010;235:32–9.

9. Lee M, Bae MA. Docosahexaenoic acid induces apoptosis in CYP2E1-containing HepG2 cells by activating the c-Jun N-terminal protein kinase related mitochondrial damage. J Nutr Biochem. 2007;18:348–54.

10. Zhang C, He M, Ni L, He K, Su K, Deng Y, Li Y, Xia H. The Role of arachidonic acid metabolism in myocardial ischemia-reperfusion injury. Cell Biochem Biophys. 2020;78:255–65.

11. Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. Deregulation of the genes that are involved in drug absorption, distribution, metabolism, and excretion in hepatocellular carcinoma. J Pharmacol Exp Ther. 2016;359:83–93.

12. Couto N, Al-Majdoub ZM, Achour B, Wright PC, Barber J. Quantification of proteins involved in drug metabolism and disposition in the human liver using label-free global proteomics. Mol Pharm. 2019;16:632–47.

13. Teschke R. Microsomal ethanol-oxidizing system: success over 50 years and an encouraging future. Alcohol Clin Exp Res. 2019;43:386–400.

14. Sharma M, Pecina-Slaus N. Different behaviour of DVL1, DVL2, DVL3 in astrocyte cell lines expressing human cytochrome P4502E1. J Biol Chem. 2006;281:348–57.

15. Lu Y, Wu D, Wang X, Ward SC, Cederbaum AI. Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. Free Radic Biol Med. 2010;49:1066–1067.

16. Chen Q, Cederbaum AI. Cytoxicity and apoptosis produced by cytochrome P450 2E1 in Hep G2 cells. Mol Pharmacol. 1998;53:638–48.

17. Lee M, Bae MA. Docosahexaenoic acid induces apoptosis in CYP2E1-containing HepG2 cells by activating the c-Jun N-terminal protein kinase related mitochondrial damage. J Nutr Biochem. 2007;18:348–54.

18. Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med. 2010;235:32–9.

19. Zeng T, Zhang CL, Zhao N, Guan MJ, Xiao M, Yang R, Zhao XL, Yu LH, Zhu ZP, Xie KQ. Impairment of Akt activity by CYP2E1-mediated oxidative stress is involved in chronic ethanol-induced fatty liver. Redox Biol. 2018;14:295–304.

20. Lu Y, Zhege J, Wang X, Bai J, Cederbaum AI. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology. 2008;47:1483–94.

21. Schattenberg JM, Wang Y, Rigoli RM, Koop DR, Czaja M. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology. 2004;39:444–55.

22. Wu D, Cederbaum AI. Role of p38 MAPK in CYP2E1-dependent arachidonic acid toxicity. J Biol Chem. 2003;278:1115–24.

23. Xu X, Yu Y, Sang R, Li J, Ge B, Zhang Y. Protective effects of taxatexene against ethanol-induced liver injury by regulating CYP2E1/Nrf2/HO-1 and NF-kappaB signaling pathways in mice. Oxid Med Cell Longev. 2018;2018:8284107.

24. Liu J, Ding X, Hu W, Ren B, Li W, Lv H, Chen J. Hepatoprotective effect of loquat leaf flavonoids in PM25-induced non-alcoholic fatty liver disease via regulation of IRS-1/Akt and CYP2E1/JNK pathways. Int J Mol Sci. 2019;19:3305.

25. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.

26. Schulze K, Imbeaud S, Letouze E, Alexandre NB, Calderaro J, Reboissou S, Coughy G, Meiller C, Shinde J, Soysouvanh F, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.

27. Zhang H, Yang X, Zhu L, Li Z, Zuo P, Wang P, Feng J, Mi Y, Zhang C, Xu Y, et al. ASPM promotes hepatocellular carcinoma progression by activating Wnt/beta-catenin signaling through antagonizing autophagy-mediated Dvl2 degradation. FEBS Open Bio. 2021;11(10):2784.

28. Seitz HK. The role of cytochrome P4502E1 in the pathogenesis of alcoholic liver disease and carcinogenesis. Chem Biol Interact. 2020;316:108918.

29. Gao C, Chen YG. Dishevelled: the hub of Wnt signalling. Cell Signal. 2010;22:717–27.

30. Angers S, Thorpe CJ, Biechele TL, Goldenberg SJ, Zheng N, MacCoss MJ, Moon RT. The KLH12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation. Nat Cell Biol. 2006;8:348–57.

31. Wu D, Cederbaum AI. Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1. J Biol Chem. 1996;271:23394–9.

32. Wu D, Cederbaum AI. Ethanol-induced apoptosis to stable HepG2 cell lines expressing human cytochrome P-4502E1. Alcohol Clin Exp Res. 1999;23:67–76.

33. Abitbol S, Dahmani R, Coulouam C, Ragazzon B, Mlecnik B, Senni N, Savall M, Bossard P, Sohier P, Drouet V, et al. AXIN deficiency in human and mouse hepatocyes induces hepatocellular carcinoma in the absence of beta-catenin activation. J Hepatol. 2018;68:1203–13.

34. Kafka A, Bacic M, Tomas D, Zarkovic K, Bukiocak A, Njirec N, Mrak G, Krsnik Z, Pecina-Slaus N. Different behaviour of DVL1, DVL2, DVL3 in astrocytoma malignancy grades and their association to TCFL1 and LEF1 upregulation. J Cell Mol Med. 2019;23:641–55.

35. Nagahata T, Shimada T, Harada A, Nagai H, Onda M, Yokoyama S, Shiba T, Jin E, Kawamori O, Emi M. Amplification, up-regulation and over-expression of DVL1, the human counterpart of the Drosophila dishevelled gene, in primary breast cancers. Cancer Sci. 2003;94:515–8.

36. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003;22:7218–21.
37. Zhang C, Li C, Chen X, Zhou Y, Yin B, Ni R, Zhang Y, Liu J. Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma. Clin Transl Oncol. 2017;19:1507–17.

38. Wei W, Li M, Wang J, Nie F, Li L. The E3 ubiquitin ligase ITCH negatively regulates canonical Wnt signaling by targeting dishevelled protein. Mol Cell Biol. 2012;32:3903–12.

39. Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol. 2004;44:27–42.

40. Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Radic Biol Med. 2017;104:144–64.

41. Korswagen HC. Regulation of the Wnt/beta-catenin pathway by redox signaling. Dev Cell. 2006;10:687–8.

42. Shin SY, Kim CG, Jho EH, Rho MS, Kim YS, Kim YH, Lee YH. Hydrogen peroxide negatively modulates Wnt signaling through downregulation of beta-catenin. Cancer Lett. 2004;212:225–31.

43. Mao J, Wang D, Wang Z, Tian W, Li X, Duan J, Wang Y, Yang H, You L, Cheng Y, et al. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/beta-catenin pathway. Cancer Lett. 2016;380:134–43.

44. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ, Morrison SJ. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527:186–91.

45. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549–56.

46. Chandel NS, Tuveson DA. The promise and perils of antioxidants for cancer patients. N Engl J Med. 2014;371:177–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.